Here are the 10-K annual reports from Ginkgo Bioworks Holdings WTS (DNABW) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow DNABW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DNABW filings page.
Ginkgo Bioworks Holdings reported 2025 revenue of $170.2 million, down from $227.0 million in 2024, as both cell engineering and biosecurity revenue declined. The company’s net loss narrowed to $312.8 million from $547.0 million, helped by large reductions in research and development and general and administrative expenses.
R&D spending fell to $243.8 million and G&A to $183.3 million, reflecting a restructuring begun in 2024, lower headcount and reduced facilities and professional costs. Adjusted EBITDA improved to a loss of $167.0 million from a loss of $293.3 million, showing progress but continued heavy cash burn.
Biosecurity service revenue declined to $37.4 million on weaker government work, while new cell engineering tools such as Datapoints and automation systems drove higher "cost of other revenue" as those offerings scaled. The company ended 2025 with $167.2 million in cash and equivalents and $255.4 million in marketable securities and believes this liquidity will fund operations for at least 12 months.